Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs

Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used medications. NSAIDs profoundly modify prostaglandin homeostasis through inhibition of the enzyme, cyclooxygenase (COX), especially COX-2. COX-2 inhibition is associated with adverse cardiovascular outcomes as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in cardiovascular medicine 2015-11, Vol.25 (8), p.726-735
Hauptverfasser:	Anwar, Asif, MD, John Anwar, Imran, MS, Delafontaine, Patrice, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute coronary syndromes Adult Aged Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Arthritis Aspirin Cardiovascular Cardiovascular disease Cardiovascular Diseases - enzymology Cardiovascular Diseases - etiology Cardiovascular Diseases - physiopathology Case-Control Studies Cell growth Cyclooxygenase 1 - drug effects Cyclooxygenase 1 - metabolism Cyclooxygenase 2 - drug effects Cyclooxygenase 2 - metabolism Cytokines Drug dosages Enzymes Female Follow-Up Studies Gene expression Growth factors Heart attacks Homeostasis Homeostasis - drug effects Humans Inflammation Lactones - adverse effects Lactones - therapeutic use Male Middle Aged Naproxen - adverse effects Naproxen - therapeutic use Patients Prevalence Randomized Controlled Trials as Topic Risk Assessment Rodents Smooth muscle Studies Sulfones - adverse effects Sulfones - therapeutic use Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used medications. NSAIDs profoundly modify prostaglandin homeostasis through inhibition of the enzyme, cyclooxygenase (COX), especially COX-2. COX-2 inhibition is associated with adverse cardiovascular outcomes as demonstrated by recent trials using this type of drug. This review explores the latest available data, including recent, randomized, clinical trials, controversies, and pathophysiology of the adverse effects of COX-inhibition.
ISSN:	1050-1738 1873-2615
DOI:	10.1016/j.tcm.2015.03.006